GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » PS Ratio

NaviFUS (ROCO:6872) PS Ratio : 72.34 (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is NaviFUS PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NaviFUS's share price is NT$28.50. NaviFUS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.39. Hence, NaviFUS's PS Ratio for today is 72.34.

Good Sign:

NaviFUS Corp stock PS Ratio (=71.07) is close to 2-year low of 67.62

The historical rank and industry rank for NaviFUS's PS Ratio or its related term are showing as below:

ROCO:6872' s PS Ratio Range Over the Past 10 Years
Min: 67.62   Med: 76.65   Max: 93.72
Current: 71.83

During the past 6 years, NaviFUS's highest PS Ratio was 93.72. The lowest was 67.62. And the median was 76.65.

ROCO:6872's PS Ratio is ranked worse than
81.8% of 1000 companies
in the Biotechnology industry
Industry Median: 9.29 vs ROCO:6872: 71.83

NaviFUS's Revenue per Sharefor the six months ended in Dec. 2023 was NT$0.04. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.39.

During the past 12 months, the average Revenue per Share Growth Rate of NaviFUS was 14.90% per year.

Back to Basics: PS Ratio


NaviFUS PS Ratio Historical Data

The historical data trend for NaviFUS's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS PS Ratio Chart

NaviFUS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - - 68.92 70.80

NaviFUS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 68.92 - 70.80

Competitive Comparison of NaviFUS's PS Ratio

For the Biotechnology subindustry, NaviFUS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NaviFUS's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NaviFUS's PS Ratio distribution charts can be found below:

* The bar in red indicates where NaviFUS's PS Ratio falls into.



NaviFUS PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

NaviFUS's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=28.50/0.394
=72.34

NaviFUS's Share Price of today is NT$28.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NaviFUS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.39.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


NaviFUS  (ROCO:6872) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


NaviFUS PS Ratio Related Terms

Thank you for viewing the detailed overview of NaviFUS's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NaviFUS (ROCO:6872) Business Description

Traded in Other Exchanges
N/A
Address
No.246, Sec 3, Chengde Road, 12th Floor, Datong District, Taipei City, TWN, 103
NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS (ROCO:6872) Headlines

No Headlines